Biogen has launched a phase 3 trial of its monoclonal antibody, BIIB059, a potential blockbuster that has shown promise for treating individuals suffering from lupus, a chronic and debilitating autoimmune disease.

The trial plans to enroll 540 adults across 135 global sites to assess the antibody vs. a placebo over 52 weeks, the company said.

Lupus, which affects multiple organs and is linked with a greater risk of death from infection and heart disease, among other conditions, afflicts an estimated 4 million individuals worldwide.